Trial Profile

Global Registry for Long-Term Follow-up of Patients Participating in Clinical Trials with Posoleucel (ALVR105)

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 27 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Posoleucel (Primary)
Indications Adenovirus infections; Cytomegalovirus infections; Epstein-Barr virus infections; Human herpesvirus 6 infections; Human polyomavirus infections; Polyomavirus infections
Focus Adverse reactions
Acronyms ALVR105
Sponsors AlloVir; Kalaris Therapeutics

Most Recent Events

18 Mar 2025 According to a Kalaris Therapeutics media release, Kalaris Therapeutics and AlloVir merged and the combined company will operate under the name Kalaris Therapeutics.
25 Mar 2024 This trial has been Discontinued in Sweden, according to European Clinical Trials Database record.
16 Mar 2024 This trial has been Completed in Sweden, According to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com